Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWRIG012 is an inhibitor of retinoic acid-inducible gene 1 (RIG-I; IC50 = 0.71 µM for the ATPase activity).1 It completely inhibits RIG-I-agonist-induced increases in IFN-β and radical S-adenosylmethionine domain-containing protein 2 (RSAD2) levels in A549 cells at 9 µM and reduces alendronate- and lipid A-induced IFN-β production in J774.1 macrophages at 5 µM.1,2 RIG012 (5 mg/kg) decreases lung injury scores and increases survival in a mouse model of pneumonia induced by K. pneumoniae.3
WARNING This product is not for human or veterinary use.
1. Small-
2. Pretreatment with alendronate augments lipid A-
3. RIG012 assists in the treatment of pneumonia by inhibiting the RIG-